<DOC>
	<DOCNO>NCT00640549</DOCNO>
	<brief_summary>The study investigate effect atorvastatin concentration small , dense LDL HDL subfractions patient diabetes underlying mechanisms effect .</brief_summary>
	<brief_title>Atorvastatin LDL Profile Non-Insulin Dependent Diabetes Mellitus</brief_title>
	<detailed_description>This study terminate October 6 , 2004 . The study terminate prematurely high screening failure rate expect . There safety efficacy reason involve decision terminate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Male female subject diagnosis type 2 diabetes mellitus either never major adverse cardiac event ( MACE ) diagnose MACE diagnose least 6 month ago , , accord judgement treat general practitioner , receive hyperlipidemic therapy . Major adverse cardiac event ( MACE ) include myocardial infarction , coronary angioplasty , coronary artery bypass graft revascularization procedure . At Screening : Visit 1 ( week 4 ) : 1 . Male patient age &gt; 35 ≤75 year postmenopausal female patient ≤75 year diagnosis type 2 diabetes mellitus 2 . Patients euthyroid least six month 3 . Written inform consent obtain At Visit 2 ( week 0 ) : 4 . LDL cholesterol ≥130 mg/dl ( 3.3 mmol/l ) &lt; 190 mg/dl ( 4.9 mmol/l ) 5 . Triglycerides &lt; 150 mg/dl ( 1.69 mmol/l ) &lt; 600 mg/dl ( 11.3 mmol/l ) 6 . Sum LDL5 LDL6 cholesterol ≥25 mg/dl ( 0.65 mmol/l ) 7 . Follicle stimulate Hormone ( FSH ) &gt; 30 U/l female patient age &lt; 60 year FSH &gt; 20 U/l female patient age ≥60 year HbA1c &gt; 8.0 Creatine kinase ( CK ) &gt; 5 time upper limit normal Patients take lipid lower medication within 8 week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>LDL-subfractions , HDL-subfractions , non insulin dependent diabetes mellitus ( NIDDM ) , hyperlipidemia , atorvastatin</keyword>
</DOC>